AVROBIO (AVRO)
(Delayed Data from NSDQ)
$1.51 USD
+0.10 (7.09%)
Updated May 24, 2024 04:00 PM ET
After-Market: $1.51 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
AVROBIO, Inc. [AVRO]
Reports for Purchase
Showing records 101 - 114 ( 114 total )
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Fabry Update Shows Continued Biological Activity, Clinical Benefit
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Anticipated Program Updates at the Lysosomal Disease Conference Could Put a Floor on the Stock
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Financials; Fabry Update up Next in Q1:19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Business Update; Looking Forward to Process Improvements to Deliver on the Curative Potential of Lentiviral GT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
What''s OK as POC, Is Not Good Enough When the Stock Is Priced to Perfection; Target Lowered to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Pullback After Fabry Update Overdone; Gaucher Trial Open, Data Likely in 2019
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Unclassified
Lenti''s Putting ERT''s on Notice; Initiating With a Buy Rating and $47 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: AVROBIO, Inc.
Industry: Unclassified
Q2 Financials; Fabry Update Up Next Later This Year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: AVROBIO, Inc.
Industry: Unclassified
Initiating Coverage at OUTPERFORM; Gene Therapy in the Wings to Swoop ERT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D